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Introduction {#oby21629-sec-0005}
============

Managing obesity with pharmacotherapy plus lifestyle intervention can help increase the proportion of people reaching ≥5% weight loss, the regulatory benchmark for clinically meaningful weight loss [1](#oby21629-bib-0001){ref-type="ref"}, [2](#oby21629-bib-0002){ref-type="ref"}, but use of pharmacotherapy must be balanced against potential adverse effects of treatment and costs. One strategy to increase benefit versus risk in obesity pharmacotherapy is through identification of long‐term weight loss predictors. By stopping drug therapy early in patients unlikely to achieve clinical benefit, clinicians can minimize drug exposure, improve the benefit:risk ratio for the patient [3](#oby21629-bib-0003){ref-type="ref"}, and use health resources more effectively. Early weight loss, whether through lifestyle [4](#oby21629-bib-0004){ref-type="ref"}, [5](#oby21629-bib-0005){ref-type="ref"}, [6](#oby21629-bib-0006){ref-type="ref"}, [7](#oby21629-bib-0007){ref-type="ref"} or pharmacotherapy [8](#oby21629-bib-0008){ref-type="ref"}, [9](#oby21629-bib-0009){ref-type="ref"}, [10](#oby21629-bib-0010){ref-type="ref"}, [11](#oby21629-bib-0011){ref-type="ref"}, is a good predictor of long‐term weight loss. Indeed, all recently approved weight loss medication labels include "stopping rules" stating when pharmacotherapy should be discontinued if clinically relevant weight loss is not, or is unlikely to be, achieved. However, current labels provide little information on outcomes in those individuals eligible for continued treatment beyond the early milestone; reported results are for all randomized individuals.

Liraglutide is a glucagon‐like peptide‐1 analog with 97% homology to human glucagon‐like peptide‐1, a physiological regulator of appetite [12](#oby21629-bib-0012){ref-type="ref"}, [13](#oby21629-bib-0013){ref-type="ref"}. Liraglutide at doses up to 1.8 mg once daily (Victoza^®^, Novo Nordisk, Bagsvaerd, Denmark) has been licensed for glycemic control in type 2 diabetes (T2D) since 2009. More recently, liraglutide 3.0 mg (Saxenda^®^; Novo Nordisk), as an adjunct to a reduced‐calorie diet and increased physical activity, has been approved for weight management in the USA, EU, and elsewhere.

This article describes how the early treatment criterion that best predicts ≥5% weight loss with liraglutide 3.0 mg at week 56 was identified, based on data from the two largest trials in the SCALE program of phase 3a trials of liraglutide 3.0 mg for weight management. *Post hoc* analyses are presented of the efficacy and safety results from these trials by early responder status, using this early response criterion.

Methods {#oby21629-sec-0006}
=======

Trial design {#oby21629-sec-0007}
------------

The design, methods, patient populations, and results of the SCALE Obesity and Prediabetes (NCT01272219) and SCALE Diabetes (NCT01272232) trials were previously published [14](#oby21629-bib-0014){ref-type="ref"}, [15](#oby21629-bib-0015){ref-type="ref"}. Briefly, in SCALE Obesity and Prediabetes, 3,731 individuals with overweight or obesity and without diabetes (body mass index \[BMI\] ≥30 kg/m^2^ or ≥27 kg/m^2^ with ≥1 obesity‐related comorbidity) were randomized 2:1 to liraglutide 3.0 mg or placebo for 56 weeks [14](#oby21629-bib-0014){ref-type="ref"}. In SCALE Diabetes, 846 individuals with BMI ≥27 kg/m^2^ and T2D were randomized 2:1:1 to liraglutide 3.0 mg, liraglutide 1.8 mg, or placebo for 56 weeks [15](#oby21629-bib-0015){ref-type="ref"}. Both trials were double‐blind, placebo‐controlled, multicenter trials, and trial drug was given as adjunct to lifestyle intervention (500 kcal/day deficit diet and physical activity ≥150 min/week). Here, only results for liraglutide 3.0 mg and placebo are reported, referred to as "liraglutide 3.0 mg" or "placebo" hereafter. Liraglutide was initiated at a dose of 0.6 mg and dose‐escalated by 0.6 mg increments weekly to the 3.0 mg treatment dose. This was a forced dose escalation, with the dose at 3.0 mg for all individuals by week 4; investigators could delay dose escalation by 7 days in total.

Determination of early response criterion {#oby21629-sec-0008}
-----------------------------------------

We used pooled data from SCALE Obesity and Prediabetes and SCALE Diabetes to determine the optimal treatment time point and weight loss threshold for identifying subjects likely to achieve ≥5% loss of initial body weight after 56 weeks' treatment. Given the objective of the analysis (predictive value for 1‐year weight loss), only trials of minimum 1‐year duration were eligible. Two of the four phase 3a trials were excluded: SCALE Sleep Apnea because it was a 32‐week trial and SCALE Maintenance because it required individuals to lose ≥5% weight through diet and exercise before randomization; thus their initial weight loss after randomization would not have represented general practice. The pooled analysis was predefined with the FDA before individual trial data became available. For mean weight loss in Table [1](#oby21629-tbl-0001){ref-type="table-wrap"}, only subjects with body weight measurements at baseline and the specific time point being analyzed (8, 12, 16 weeks) and week 56 contributed to the analysis. For identifying individuals with ≥5% weight loss at week 56, missing data were imputed using last observation carried forward (LOCF). Reasons for choosing these time points are in the Supporting Information.

###### 

Positive and negative predictive values for achieving ≥5% weight loss with liraglutide 3.0 mg at 56 weeks using different early response criteria: pooled analysis of the SCALE Obesity and Prediabetes and SCALE Diabetes trials

  Week     Early response criterion (%)   *N*     Early response, *n* (%)   Mean week 56 weight change (%) in early responders   Positive predictive value, *n* (%)[a](#oby21629-note-0005){ref-type="fn"}   Early nonresponse, *n* (%)   Mean week 56 weight change (%) in early nonresponders   Negative predictive value, *n* (%)[b](#oby21629-note-0006){ref-type="fn"}   Correctly predicted, *n* (%)[c](#oby21629-note-0007){ref-type="fn"}
  -------- ------------------------------ ------- ------------------------- ---------------------------------------------------- --------------------------------------------------------------------------- ---------------------------- ------------------------------------------------------- --------------------------------------------------------------------------- ---------------------------------------------------------------------
  **8**    3                              2,653   2,035 (76.7)              −10.09                                               1,544 (75.9)                                                                618 (23.3)                   −3.69                                                   439 (71.0)                                                                  1,983 (74.7)
           4                                      1,644 (62.0)              −11.00                                               1,373 (83.5)                                                                1,009 (38.0)                 −4.53                                                   659 (65.3)                                                                  2,032 (76.6)
           5                                      1,245 (46.9)              −12.10                                               1,096 (88.0)                                                                1,408 (53.1)                 −5.46                                                   781 (55.5)                                                                  1,877 (70.8)
  **12**   3                              2,578   2,084 (80.8)              −9.98                                                1,601 (76.8)                                                                494 (19.2)                   −2.79                                                   389 (78.7)                                                                  1,990 (77.2)
           4                                      1,821 (70.6)              −10.68                                               1,485 (81.5)                                                                757 (29.4)                   −3.56                                                   536 (70.8)                                                                  2,021 (78.4)
           5                                      1,515 (58.8)              −11.55                                               1,312 (86.6)                                                                1,063 (41.2)                 −4.37                                                   669 (62.9)                                                                  1,981 (76.8)
  **16**   3                              2,519   2,099 (83.3)              −9.95                                                1,609 (76.7)                                                                420 (16.7)                   −2.29                                                   338 (80.5)                                                                  1,947 (77.3)
           4                                      1,893 (75.1)              −10.46                                               1,541 (81.4)                                                                626 (24.9)                   −3.02                                                   476 (76.0)                                                                  2,017 (80.1)
           5                                      1,637 (65.0)              −11.21                                               1,411 (86.2)                                                                882 (35.0)                   −3.78                                                   602 (68.3)                                                                  2,013 (79.9)

Week 56 response is defined as at least a 5% reduction in body weight. If data were missing for week 56, the last available body weight measurement was used (i.e., missing data were imputed using last observation carried forward). Mean weight loss is based on observed data only.

Positive predictive value is defined as the percentage of early responders who were week 56 responders.

Negative predictive value is defined as the percentage of early nonresponders who were week 56 nonresponders.

Correctly predicted proportion = (number of correctly predicted week 56 responders + number of correctly predicted week 56 nonresponders)/(total number of subjects).

The ability to predict response status after 56 weeks was evaluated by the positive predictive value (PPV; i.e., proportion of subjects with an early response who had ≥5% weight loss after 56 weeks) and the negative predictive value (NPV; i.e., proportion of subjects with an early nonresponse who had \<5% weight loss after 56 weeks) for ≥3%, 4%, and 5% weight loss at 8, 12, and 16 weeks. The proportions of "correctly predicted overall" were calculated from PPV and NPV (Table [1](#oby21629-tbl-0001){ref-type="table-wrap"}). The sensitivity and specificity of these criteria were also evaluated (Supporting Information).

The pooled analysis was repeated for male and female subjects, and the results were also analyzed separately by trial, to ensure that the identified cut point for defining early response would be valid for both sexes and for subjects with or without T2D. A sensitivity analysis was also performed in which missing week 56 responses were imputed as nonresponse, rather than using LOCF.

*Post hoc* analysis of end points by early response status {#oby21629-sec-0009}
----------------------------------------------------------

Once the optimal early response criterion was identified, subjects were classified as early responders (ERs) or early nonresponders (ENRs). We then assessed efficacy outcomes at week 56 for ERs and ENRs, based on individuals who completed 56 weeks' treatment. Weight end points were mean change in body weight from baseline and the proportion of patients with a weight loss of ≥5%, \>10%, and \>15% at week 56. Secondary efficacy outcomes were the changes from baseline to week 56 in HbA~1c~, fasting plasma glucose, systolic (SBP) and diastolic blood pressure (DBP), BMI, waist circumference, heart rate, fasting lipid profile, and various additional cardiometabolic biomarkers. Changes in the following health‐related quality of life (HRQoL) scores were also evaluated: Impact of Weight on Quality of Life‐Lite (IWQOL‐Lite) total score and physical function score [16](#oby21629-bib-0016){ref-type="ref"} (both trials); and Short Form‐36 (SF‐36) physical component summary score [17](#oby21629-bib-0017){ref-type="ref"} (SCALE Obesity and Prediabetes only).

Efficacy outcomes are reported for ERs and ENRs who completed 56 weeks' treatment. Safety is reported based on the safety analysis set for ERs and ENRs (i.e., all subjects with data at week 16, regardless of whether they completed 56 weeks' treatment) (Figure [1](#oby21629-fig-0001){ref-type="fig"}). The results are reported by trial for ERs and ENRs to liraglutide 3.0 mg or placebo so that any potential differences in clinical outcomes in patients with T2D would not be masked due to the relatively small size of this study population.

![Subject disposition for results of *post hoc* analyses. Early responders (ERs), individuals who achieved ≥4% weight loss from baseline at 16 weeks; early nonresponders (ENRs), individuals who achieved \<4% weight loss from baseline at 16 weeks. Full analysis set (FAS): in order to be defined as ER/ENR at week 16, individuals had to have a fasting body weight measurement at baseline and the week 16 visit. Completers at week 56 were individuals with a body weight measurement at week 56. Only individuals satisfying the respective criteria are shown. \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](OBY-24-2278-g001){#oby21629-fig-0001}

Statistical analysis {#oby21629-sec-0010}
--------------------

For the pooled analysis to assess the optimal response criterion, no covariate adjustments were made. Missing response status after 56 weeks was imputed using LOCF. The observed mean weight loss was plotted during the course of the trial (Figure [2](#oby21629-fig-0002){ref-type="fig"}).

![Fasting body weight loss by early responder status. Line graphs are observed means (±SE) for ERs/ENRs who completed 56 weeks. Fasting visit data only. ERs, early responders (individuals who achieved ≥4% weight loss from baseline at 16 weeks); ENRs, early nonresponders (individuals who achieved \<4% weight loss from baseline at 16 weeks); SE, standard error. Note that ENRs continued on treatment until week 56; in clinical practice, treatment would cease for ENRs in line with the stopping rule.](OBY-24-2278-g002){#oby21629-fig-0002}

Analyses of outcomes at week 56 were performed in trial completers split by ER and ENR status. The analyses of outcomes used the same model as in the individual trials [14](#oby21629-bib-0014){ref-type="ref"}, [15](#oby21629-bib-0015){ref-type="ref"}. The model included treatment, country, sex, and interaction between BMI strata and prediabetes status as fixed effects, with baseline body weight as covariate. In the SCALE Diabetes ANCOVA model, BMI stratification and prediabetes status was replaced by baseline HbA~1c~ stratification and background medication. Continuous variables were estimated using ANCOVA, as described above; categorical variables were estimated using a logistic regression model with the same fixed effects and covariates as the relevant ANCOVA. Efficacy data are estimated means or estimated proportions; safety data are observed proportions or observed means.

Statistical analyses were conducted using SAS version 9.3 (SAS Institute Inc., Cary, NC). As ERs and ENRs are not randomized populations, differences between them were not quantified or analyzed statistically.

Results {#oby21629-sec-0011}
=======

Subject disposition by trial for the individuals covered in these analyses (i.e., those with body weight measurement at baseline and weeks 16 and 56) is shown in Figure [1](#oby21629-fig-0001){ref-type="fig"}.

Optimal early response criterion for ≥5% weight loss after 56 weeks {#oby21629-sec-0012}
-------------------------------------------------------------------

The proportion of subjects treated with liraglutide 3.0 mg who lost ≥3%, ≥4%, or ≥5% weight at 8, 12, and 16 weeks in the pooled analysis of SCALE Obesity and Prediabetes and SCALE Diabetes and associated PPVs and NPVs are shown in Table [1](#oby21629-tbl-0001){ref-type="table-wrap"}. The sensitivity and specificity of each criterion were also calculated (Supporting Information Table S1).

The analyses showed that ≥4% weight loss at 16 weeks yielded the highest correctly predicted value (80.1%), consistent with high values for both PPV (81.4%) and NPV (76.0%) (Table [1](#oby21629-tbl-0001){ref-type="table-wrap"}). The criteria based on the 8‐week time point were associated with lower overall correctly predicted values and, in particular, low NPVs, meaning that treatment would have been incorrectly discontinued in a notable number of individuals who would have gone on to achieve ≥5% weight loss after 56 weeks. For example, using NPV for 4% weight loss at 8 weeks, 34.7% (350 of 1,009 subjects identified as ENRs) would have been incorrectly discontinued, versus 24% (150 of 626 subjects) using the 16‐week value (Table [1](#oby21629-tbl-0001){ref-type="table-wrap"}). The 12‐week time point criteria had PPVs similar to those at the 16‐week time point but comparatively lower NPVs (Table [1](#oby21629-tbl-0001){ref-type="table-wrap"}). Thus, using NPV for 4% weight loss at 12 weeks, 29.2% (221 of 757 subjects identified as ENRs) would have been incorrectly discontinued, versus 24% (150 of 626 subjects) using the 16‐week value (Table [1](#oby21629-tbl-0001){ref-type="table-wrap"}). Furthermore, the choice of week 16 meant that individuals would have received treatment‐dose liraglutide 3.0 mg for 12 weeks, consistent with the exposure period generally recommended for other antiobesity medications.

Consistent results and conclusions were reached when the pooled analysis was conducted separately for males and females, or for each trial, and from a sensitivity analysis with missing week 56 responses imputed as nonresponse (Supporting Information Tables S2‐S4).

A separate analysis showed that ≥4% weight loss at 16 weeks was also a good criterion for predicting weight loss with placebo, yielding a high overall correctly predicted value (80.0%), consistent with a reasonably high PPV (66.1%) and NPV (85.8%) (Supporting Information Table S5).

Early responder populations {#oby21629-sec-0013}
---------------------------

Among individuals on liraglutide 3.0 mg with a week 16 measurement, 77.3% without T2D and 62.7% with T2D were ERs, and 22.7% and 37.3% were ENRs. The proportions of individuals who were ERs to placebo were much lower than with liraglutide 3.0 mg: 30.5% of individuals without T2D and 20.5% with T2D.

Demographic and other baseline characteristics of all randomized subjects, as well as ERs and ENRs in each trial, are shown in Tables [2](#oby21629-tbl-0002){ref-type="table-wrap"} and [3](#oby21629-tbl-0003){ref-type="table-wrap"}. The "all‐randomized" group included individuals who discontinued the trial before week 16, while the ER/ENR groups did not (by definition they could not be classified as ER or ENR).

###### 

Demographics and baseline characteristics of patients by early responder status (SCALE Obesity and Prediabetes trial)

                                      Liraglutide 3.0 mg   Placebo                                                             
  ----------------------------------- -------------------- ---------------- ---------------- ---------------- ---------------- ----------------
  **Female sex, *n* (%)**             1957 (78.7)          1151 (80.3)      251 (70.7)       971 (78.1)       205 (77.4)       415 (77.6)
  **Mean age, years \[SD\]**          45.2 \[12.1\]        46.4 \[11.6\]    45.4 \[11.8\]    45.0 \[12.0\]    47.0 \[11.7\]    45.6 \[12.1\]
  **Race, *n* (%)**                                                                                                            
  **White**                           2107 (84.7)          1238 (86.4)      289 (81.4)       1061 (85.3)      240 (90.6)       455 (85.0)
  **Black/African‐American**          242 (9.7)            126 (8.8)        41 (11.5)        114 (9.2)        15 (5.7)         51 (9.5)
  **Other**                           138 (5.5)            69 (4.8)         25 (7.0)         69 (5.5)         10 (3.8)         29 (5.4)
  **Ethnicity, *n* (%)**                                                                                                       
  **Hispanic/Latino**                 259 (10.4)           126 (8.8)        31 (8.7)         134 (10.8)       31 (11.7)        46 (8.6)
  **Non‐Hispanic/Latino**             2228 (89.6)          1307 (91.2)      324 (91.3)       1110 (89.2)      234 (88.3)       489 (91.4)
  **Mean weight, kg \[SD\]**          106.2 \[21.2\]       105.3 \[20.4\]   109.8 \[23.7\]   106.2 \[21.7\]   107.4 \[23.6\]   106.7 \[22.3\]
  **Mean BMI, kg/m^2^ \[SD\]**        38.3 \[6.4\]         38.1 \[6.3\]     38.9 \[6.8\]     38.3 \[6.3\]     38.7 \[7.1\]     38.3 \[6.4\]
  **Glycemic status, *n* (%)**                                                                                                 
  **Normoglycemic**                   959 (38.6)           528 (36.8)       151 (42.5)       487 (39.1)       100 (37.7)       196 (36.6)
  **With prediabetes**                1528 (61.4)          905 (63.2)       204 (57.5)       757 (60.9)       165 (62.3)       339 (63.4)
  **Mean HbA~1c~, % points \[SD\]**   5.6 \[0.4\]          5.6 \[0.4\]      5.6 \[0.4\]      5.6 \[0.4\]      5.6 \[0.4\]      5.6 \[0.4\]
  **Mean FPG, mg/dL \[SD\]**          95.9 \[10.6\]        96.1 \[10.4\]    97.2 \[11.3\]    95.5 \[9.8\]     95.7 \[9.2\]     95.9 \[9.9\]

Early responders, individuals who achieved ≥4% weight loss from baseline at 16 weeks; early nonresponders, individuals who achieved \<4% weight loss from baseline at 16 weeks. Based on individuals with a fasting body weight measurement at baseline and week 16 and who completed 56 weeks of treatment. "All randomized" refers to all randomized patients in the overall trial.

BMI, body mass index; FPG, fasting plasma glucose; SD, standard deviation.

###### 

Demographics and baseline characteristics of patients by early responder status (SCALE Diabetes trial)

                                                                       Liraglutide 3.0 mg   Placebo                                                             
  -------------------------------------------------------------------- -------------------- ---------------- ---------------- ---------------- ---------------- ----------------
  **Female sex, *n* (%)**                                              203 (48.0)           112 (52.3)       43 (39.1)        115 (54.2)       15 (48.4)        61 (60.4)
  **Mean age, years \[SD\]**                                           55.0 \[10.8\]        55.5 \[10.1\]    54.1 \[9.8\]     54.7 \[9.8\]     57.9 \[9.4\]     55.7 \[8.8\]
  **Race, *n* (%)**                                                                                                                                             
  **White**                                                            353 (83.5)           184 (86.0)       86 (78.2)        175 (82.5)       27 (87.1)        83 (82.2)
  **Black/African‐American**                                           44 (10.4)            16 (7.5)         14 (12.7)        27 (12.7)        3 (9.7)          13 (12.9)
  **Other**                                                            26 (6.1)             14 (6.5)         10 (9.1)         10 (4.7)         1 (3.2)          5 (5.0)
  **Ethnicity, *n* (%)**                                                                                                                                        
  **Hispanic/Latino**                                                  46 (10.9)            19 (8.9)         15 (13.6)        24 (11.3)        3 (9.7)          9 (8.9)
  **Non‐Hispanic/Latino**                                              375 (88.7)           193 (90.2)       95 (86.4)        187 (88.2)       28 (90.3)        92 (91.1)
  **Mean weight, kg \[SD\]**                                           105.7 \[21.9\]       106.8 \[21.3\]   102.8 \[19.5\]   106.5 \[21.3\]   109.3 \[18.6\]   104.7 \[22.1\]
  **Mean BMI, kg/m^2^ \[SD\]**                                         37.1 \[6.5\]         37.7 \[6.5\]     36.1 \[6.3\]     37.4 \[7.1\]     37.7 \[5.7\]     37.4 \[7.6\]
  **Mean HbA~1c~, % points \[SD\]**                                    7.9 \[0.8\]          7.9 \[0.8\]      8.0 \[0.8\]      7.9 \[0.8\]      7.6 \[0.5\]      7.8 \[0.7\]
  **Mean FPG, mg/dL \[SD\]** [a](#oby21629-note-0009){ref-type="fn"}   158.4 \[32.8\]       158.5 \[34.8\]   157.7 \[27.9\]   155.5 \[33.0\]   151.4 \[33.0\]   149.6 \[30.0\]

Overall values are based on the full analysis set (*N* = 407 and 211, respectively).

Early responders, individuals who achieved ≥4% weight loss from baseline at 16 weeks; early nonresponders, individuals who achieved \<4% weight loss from baseline at 16 weeks. Based on individuals with a fasting body weight measurement at baseline and week 16 and who completed 56 weeks of treatment. "All randomized" refers to all randomized patients in the overall trial.

BMI, body mass index; FPG, fasting plasma glucose; SD, standard deviation.

In general, baseline characteristics in the ER and ENR groups appeared similar across treatment groups within each trial. In both liraglutide 3.0 mg and placebo groups, individuals of White origin appeared more prevalent in the ER versus ENR groups, and female sex appeared consistently associated with early response to liraglutide 3.0 mg (see percentages, Supporting Information Table S3) but not to placebo in individuals with and without T2D.

Weight loss at week 56 in ERs and ENRs {#oby21629-sec-0014}
--------------------------------------

In SCALE Obesity and Prediabetes, weight loss in ERs to liraglutide 3.0 mg was 10.8% (11.2 kg) versus 3.0% (3.2 kg) for ENRs (Figure [2](#oby21629-fig-0002){ref-type="fig"}A). Similarly, in SCALE Diabetes, ERs had a greater mean weight loss than ENRs (8.5% \[9.0 kg\] vs. 3.1% \[3.2 kg\]) at 56 weeks (Figure [2](#oby21629-fig-0002){ref-type="fig"}B). ERs to placebo also achieved greater weight loss than ENRs to placebo (Figure [2](#oby21629-fig-0002){ref-type="fig"}).

The proportions of ERs and ENRs achieving ≥5%, \>10%, and \>15% weight loss at week 56 in both trials were always greater for ERs versus ENRs to liraglutide 3.0 mg (Figure [3](#oby21629-fig-0003){ref-type="fig"}). The same pattern was observed for placebo, although proportions achieving each category were smaller than for liraglutide 3.0 mg.

![Categorical weight loss at week 56. Proportions of subjects are estimated proportions from a logistic regression model for ERs/ENRs who completed 56 weeks of treatment. ERs, early responders (individuals who achieved ≥4% weight loss from baseline at 16 weeks); ENR, early nonresponders (individuals who achieved \<4% weight loss from baseline at 16 weeks).](OBY-24-2278-g003){#oby21629-fig-0003}

Secondary end points at week 56 in ERs and ENRs {#oby21629-sec-0015}
-----------------------------------------------

In SCALE Obesity and Prediabetes, changes in all cardiometabolic biomarkers examined, except heart rate, appeared to be more favorable in ERs than ENRs to liraglutide 3.0 mg, consistent with greater weight loss (Table [4](#oby21629-tbl-0004){ref-type="table-wrap"}, Supporting Information Table S6a). In particular, greater improvements were observed in ERs versus ENRs to liraglutide 3.0 mg for SBP, HDL cholesterol, LDL cholesterol, total cholesterol, and triglycerides. Most changes were also more favorable in ERs versus ENRs to placebo. With liraglutide 3.0 mg, pulse rate increased by 2.7 beats per minute (bpm) in ERs and 2.6 bpm in ENRs. With placebo, pulse rate changes were −1.2 and +0.2 bpm, respectively. Improvements in the IWQOL‐Lite total score and physical function score and the SF‐36 physical component summary score were reported by all groups, but appeared greater in ERs versus ENRs to both liraglutide 3.0 mg and placebo (Table [4](#oby21629-tbl-0004){ref-type="table-wrap"}, Supporting Information Table S6a).

###### 

Changes from baseline in selected secondary end points (SCALE Obesity and Prediabetes trial)

                                         Liraglutide 3.0 mg   Placebo                                                                    
  -------------------------------------- -------------------- ---------------- ------- ---------------- ------- ---------------- ------- ----------------
  **HbA~1c~ (% points)**                 5.6                  −0.36 \[0.01\]   5.6     −0.23 \[0.01\]   5.6     −0.17 \[0.02\]   5.6     −0.06 \[0.01\]
  **FPG (mg/dL)**                        96.1                 −8.2 \[0.2\]     97.2    −6.3 \[0.5\]     95.7    −2.3 \[0.5\]     95.9    +0.9 \[0.4\]
  **SBP (mm Hg)**                        123.4                −5.1 \[0.3\]     123.8   −2.0 \[0.6\]     123.0   −2.3 \[0.7\]     124.0   −1.8 \[0.5\]
  **DBP (mm Hg)**                        78.9                 −3.3 \[0.2\]     78.6    −1.4 \[0.4\]     78.3    −3.0 \[0.5\]     79.4    −2.1 \[0.3\]
  **Pulse (bpm)**                        71.2                 +2.7 \[0.2\]     70.8    +2.6             71.0    −1.2             71.0    +0.2
  **HDL cholesterol, mg/dL (%)** ^a^     51.8                 +3.9 \[0.4\]     52.0    +0.0 \[0.8\]     51.9    +4.8 \[0.9\]     50.9    −1.0 \[0.6\]
  **LDL cholesterol, mg/dL (%)** ^a^     111.4                −3.6 \[0.5\]     113.2   −0.9 \[1.1\]     115.6   −2.0 \[1.3\]     111.7   −1.0 \[0.9\]
  **Total cholesterol, mg/dL (%)** ^a^   193.0                −3.2 \[0.3\]     196.7   −1.7 \[0.7\]     198.6   −1.7 \[0.8\]     193.9   −0.9 \[0.6\]
  **Triglycerides, mg/dL (%)** ^a^       125.2                −15.3 \[0.7\]    129.4   −7.1 \[1.6\]     128.3   −12.8 \[1.8\]    130.3   −2.5 \[1.4\]
  **IWQOL-Lite total score**             73.0                 +12.7            70.7    +8.2             72.7    +13.0            73.9    +6.3

Baseline value is in mg/dL, and change is presented as relative change.

Early responders, individuals who achieved ≥4% weight loss from baseline at 16 weeks; early nonresponders, individuals who achieved \<4% weight loss from baseline at 16 weeks. Based on individuals with a fasting body weight measurement at baseline and week 16 and who completed 56 weeks of treatment. Changes are estimated mean changes from baseline to week 56 from an ANCOVA. Missing values post‐baseline were imputed using last observation carried forward. Additional end points are reported in Supporting Information Table S6a, b.

DBP, diastolic blood pressure; FPG, fasting plasma glucose; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; IWQOL‐Lite, Impact of Weight on Quality of Life‐Lite; SBP, systolic blood pressure.

Similarly in SCALE Diabetes, changes in most cardiometabolic biomarkers and HRQoL scores appeared more favorable in ERs than ENRs (Table [5](#oby21629-tbl-0005){ref-type="table-wrap"}, Supporting Information Table S6b). Notably, improvements in glycemic markers were observed in both ERs and ENRs to liraglutide 3.0 mg.

###### 

Changes from baseline in selected secondary end points (SCALE Diabetes trial)

                                                                            Liraglutide 3.0 mg   Placebo                                                                    
  ------------------------------------------------------------------------- -------------------- ---------------- ------- ---------------- ------- ---------------- ------- ----------------
  **HbA~1c~ (% points)**                                                    7.9                  −1.60 \[0.05\]   8.0     −1.11 \[0.08\]   7.6     −1.17 \[0.14\]   7.7     −0.30 \[0.09\]
  **FPG (mg/dL)**                                                           158.5                −44.2 \[2.4\]    157.7   −30.1 \[30.3\]   151.4   −30.4 \[6.2\]    151.4   −1.9 \[3.7\]
  **SBP (mm Hg)**                                                           128.4                −3.3 \[0.8\]     129.1   −1.3 \[1.1\]     128.7   −3.2 \[2.1\]     129.8   +0.7 \[1.2\]
  **DBP (mm Hg)**                                                           78.5                 −0.6 \[0.5\]     79.9    −1.8 \[0.8\]     78.5    −2.1 \[0.4\]     79.3    −1.0 \[0.8\]
  **Pulse (bpm)**                                                           74.0                 +1.7 \[0.6\]     72.1    +3.1 \[0.8\]     74.3    −3.8 \[1.5\]     73.4    −1.4 \[0.8\]
  **HDL cholesterol, mg/dL (%)** [a](#oby21629-note-0012){ref-type="fn"}    45.3                 +7.2 \[1.0\]     46.2    +0.7 \[1.3\]     43.7    +7.7 \[2.6\]     45.6    +0.6 \[1.3\]
  **LDL cholesterol, mg/dL (%)** [a](#oby21629-note-0012){ref-type="fn"}    85.1                 +1.6 \[1.9\]     91.7    −0.3 \[2.5\]     76.7    +2.5 \[4.9\]     79.8    +4.1 \[2.7\]
  **Total cholesterol, mg/dL(%)** [a](#oby21629-note-0012){ref-type="fn"}   169.1                −1.5 \[1.0\]     175.6   −1.1 \[1.5\]     159.3   +0.3 \[2.8\]     164.2   +3.9 \[1.6\]
  **Triglycerides, mg/dL (%)** [a](#oby21629-note-0012){ref-type="fn"}      162.0                −19.2 \[2.1\]    155.8   −6.9 \[3.3\]     163.6   −12.7 \[5.9\]    157.2   +3.2 \[3.8\]
  **IWQOL‐Lite total score**                                                69.7                 +13.2 \[0.8\]    79.5    +7.9 \[1.1\]     73.8    +10.8 \[2.1\]    75.9    +7.2 \[1.2\]

Baseline value is in mg/dL, and change is presented as relative change.

Early responders, individuals who achieved ≥4% weight loss from baseline at 16 weeks; early nonresponders, individuals who achieved \<4% weight loss from baseline at 16 weeks. Based on individuals with a fasting body weight measurement at baseline and week 16 and who completed 56 weeks of treatment. Changes are estimated mean changes from baseline to week 56 from an ANCOVA. Missing values post‐baseline were imputed using last observation carried forward. Additional end points are reported in Supporting Information Table S6a, b.

DBP, diastolic blood pressure; FPG, fasting plasma glucose; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; IWQOL‐Lite, Impact of Weight on Quality of Life‐Lite; SBP, systolic blood pressure.

Safety {#oby21629-sec-0016}
------

Safety results for the randomized populations in both trials were reported previously [14](#oby21629-bib-0014){ref-type="ref"}, [15](#oby21629-bib-0015){ref-type="ref"}. The most common adverse events (AEs), occurring more frequently with liraglutide 3.0 mg versus placebo, were gastrointestinal.

An overview of safety results by early responder status is shown in Tables [6](#oby21629-tbl-0006){ref-type="table-wrap"} and [7](#oby21629-tbl-0007){ref-type="table-wrap"}. AEs occurring in ≥5% of individuals treated with liraglutide 3.0 mg and more frequently with liraglutide 3.0 mg than placebo are listed by preferred term in Supporting Information Table S7. AE rates were generally comparable between ERs and ENRs to liraglutide 3.0 mg, and comparable to the overall trial population, except that in SCALE Diabetes, rates of gastrointestinal‐ or appetite‐related AEs were higher in ERs versus ENRs.

###### 

Overview of adverse events in the overall trial and in early responders and early nonresponders (SCALE Obesity and Prediabetes trial)

                                 Liraglutide 3.0 mg   Placebo                                                 
  ------------------------------ -------------------- -------------- ------------ -------------- ------------ ------------
  **Adverse events**             2,285 (92.1)         1,559 (93.5)   453 (92.3)   1,043 (84.0)   285 (88.5)   651 (88.6)
  **Serious adverse events**     154 (6.2)            106 (6.4)      24 (4.9)     62 (5.0)       21 (6.5)     33 (4.5)
  **Severe adverse events**      304 (12.3)           190 (11.4)     51 (10.4)    113 (9.1)      36 (11.2)    66 (9.0)
  **Fatal**                      1 (0.0)              0 (0.0)        1 (0.2)      2 (0.2)        0 (0.0)      0 (0.0)
  **Leading to withdrawal^a^**   244 (9.8)            54 (3.2)       20 (4.1)     47 (3.8)       4 (1.2)      17 (2.3)

AE data given as *n* (% of patients). Safety analysis set (for ERs and ENRs, all subjects with data at week 16).

^a^Withdrawal rates cover the entire trial period for "All randomized" and week 16 onwards for ERs and ENRs.

ERs, early responders (individuals who achieved ≥4% weight loss from baseline at 16 weeks); ENRs, early nonresponders (individuals who achieved \<4% weight loss from baseline at 16 weeks).

###### 

Overview of adverse events in the overall trial and in early responders and early nonresponders (SCALE Diabetes trial)

                                                                      Liraglutide 3.0 mg   Placebo                                            
  ------------------------------------------------------------------- -------------------- ------------ ------------ ------------ ----------- ------------
  **Adverse events**                                                  392 (92.9)           222 (96.9)   124 (91.2)   182 (85.8)   32 (94.1)   120 (90.9)
  **Serious adverse events**                                          37 (8.8)             17 (7.4)     15 (11.0)    13 (6.1)     1 (2.9)     10 (7.6)
  **Severe adverse events**                                           52 (12.3)            30 (13.1)    14 (10.3)    21 (9.9)     1 (2.9)     17 (12.9)
  **Fatal**                                                           0 (0.0)              0 (0.0)      0 (0.0)      0 (0.0)      0 (0.0)     0 (0.0)
  **Leading to withdrawal** [a](#oby21629-note-0016){ref-type="fn"}   39 (9.2)             7 (3.1)      6 (4.4)      7 (3.3)      0 (0.0)     3 (2.3)

AE data given as *n* (% of patients).

Safety analysis set (for ERs and ENRs, all subjects with data at week 16).

Withdrawal rates cover the entire trial period for "All randomized" and week 16 onwards for ERs and ENRs.

One subject did not receive treatment and was excluded from the safety analysis set for SCALE Diabetes.

ERs, early responders (individuals who achieved ≥4% weight loss from baseline at 16 weeks); ENRs, early nonresponders (individuals who achieved \<4% weight loss from baseline at 16 weeks).

In SCALE Obesity and Prediabetes, pancreatitis was uncommon in ERs (\<0.1/100 patient‐years' exposure \[PYE\]) and ENRs (0.2/100 PYE) to liraglutide 3.0 mg. Gallbladder disorders were more frequent in ERs (2.8% of individuals; 2.9/100 PYE) versus ENRs to liraglutide 3.0 mg (1.4%; 1.9/100 PYE). Psychiatric AEs appeared similar in ER and ENRs.

In SCALE Diabetes, no events of pancreatitis were reported, and there were too few gallbladder‐related and psychiatric AEs to allow any conclusions to be drawn. Documented symptomatic hypoglycemia, defined according to ADA criteria [18](#oby21629-bib-0018){ref-type="ref"}, was similar in ERs versus ENRs to liraglutide 3.0 mg (event rates of 79.5/100 PYE and 93.3/100 PYE, respectively).

For ERs and ENRs to placebo, results were as follows: in SCALE Obesity and Prediabetes, no pancreatitis was reported in either ERs or ENRs; gallbladder disorders occurred in 1.6% of ERs (2.2/100 PYE) and 0.5% of ENRs (0.6/100 PYE); and psychiatric AEs appeared similar in ER and ENRs. In SCALE Diabetes, documented hypoglycemia occurred at event rates of 20.5/100 PYE (ERs to placebo) and 31.1/100 PYE (ENRs to placebo).

Discussion {#oby21629-sec-0017}
==========

It is well documented that early response to a weight loss intervention can predict long‐term weight loss [8](#oby21629-bib-0008){ref-type="ref"}, [9](#oby21629-bib-0009){ref-type="ref"}, [10](#oby21629-bib-0010){ref-type="ref"}, [11](#oby21629-bib-0011){ref-type="ref"}; this is the basis for the stopping rules for all recently approved weight loss medications [19](#oby21629-bib-0019){ref-type="ref"}, [20](#oby21629-bib-0020){ref-type="ref"}, [21](#oby21629-bib-0021){ref-type="ref"}. Weight loss response after 1 to 4 months has been used to predict weight loss at 1 year. Interestingly, in the Look AHEAD study, 1‐ and 2‐month weight loss was associated with weight loss through year 8 among individuals with T2D who received an intensive lifestyle intervention [7](#oby21629-bib-0007){ref-type="ref"}.

In order to identify an optimal early response criterion for liraglutide 3.0 mg, we examined weight loss of ≥3%, 4%, or 5% at 8, 12, or 16 weeks in a pooled analysis predefined with the US FDA before trial data became available. Weight loss of ≥4% at week 16 was shown to be the best predictor of ≥5% weight loss at 56 weeks and to be appropriate for individuals with and without T2D and for both genders (Table [1](#oby21629-tbl-0001){ref-type="table-wrap"}, Supporting Information Table S1). Earlier time points would result in discontinuation of treatment in a significant number of individuals who would indeed achieve ≥5% weight loss after 56 weeks, while later time points would likely have achieved even greater predictive accuracy but were not considered as they would have entailed additional unnecessary exposure in nonresponders. Accordingly, the stopping rule in the USA specifies a weight loss of ≥4% at 16 weeks [22](#oby21629-bib-0022){ref-type="ref"}. While health authorities across the world focus on limiting treatment to those who will benefit, their approaches differ slightly. The European Medicines Agency required an early response criterion optimized to exclude individuals who were unlikely to achieve ≥10% weight loss at 56 weeks; this was best fulfilled by weight loss of ≥5% after 16 weeks (data not shown). Accordingly, the European label requires ≥5% weight loss after 12 weeks on the full 3.0 mg dose to qualify for continued treatment [23](#oby21629-bib-0023){ref-type="ref"}.

In both trials, higher proportions of subjects were early responders to liraglutide 3.0 mg than to placebo. Early responders to liraglutide achieved greater mean weight loss than early nonresponders and were more likely to achieve ≥5%, \>10%, and \>15% weight loss at 56 weeks. Greater responses were also seen among early responders versus early nonresponders to placebo; but fewer subjects were early responders to placebo compared with liraglutide 3.0 mg.

The greater weight loss in early responders was accompanied by a trend toward greater improvements in cardiometabolic biomarkers. Decreases in mean SBP and DBP and favorable changes in lipid profile, in particular, are expected effects of weight loss, contributing to a decreased risk of developing cardiovascular disease [24](#oby21629-bib-0024){ref-type="ref"}. In SCALE Diabetes, clinically meaningful reductions in HbA~1c~ and fasting plasma glucose were seen in both early responders and early nonresponders to liraglutide, due to its direct glucose‐lowering effect [25](#oby21629-bib-0025){ref-type="ref"}; in early responders, this effect appeared further enhanced by the greater weight loss versus early nonresponders. The combination of direct effects of liraglutide on glycemia, as well as further improvement likely mediated by enhanced weight loss in early responders, may be particularly beneficial for slowing progression to T2D and increasing regression to normoglycemia in individuals with prediabetes, which further reduces the risk of conversion to T2D [26](#oby21629-bib-0026){ref-type="ref"}.

It has been suggested that, in trials of antiobesity drugs, improvements in feeling and functioning should be measured when validated measures exist [27](#oby21629-bib-0027){ref-type="ref"}. Improvements in HRQoL were recorded as assessed by IWQOL‐Lite, a questionnaire developed specifically to evaluate the impact of weight on quality of life (both trials), and SF‐36, a more general HRQoL questionnaire (SCALE Obesity and Prediabetes only). For both liraglutide 3.0 mg and placebo, improvements were greater in early responders than early nonresponders. The changes recorded for early responders (to either intervention) were clinically relevant. (Clinically relevant improvements for an individual are increases of 7.7 to 12 points for IWQOL‐Lite total score, depending on baseline score [28](#oby21629-bib-0028){ref-type="ref"}, and ≥2 points for SF‐36 physical component summary score [17](#oby21629-bib-0017){ref-type="ref"}.)

The greater improvements observed in early responders, compared with early nonresponders, were generally not accompanied by an increase in AEs: the safety profiles of early responders and early nonresponders were similar within each trial, except that early responders reported higher rates of gastrointestinal disorders in SCALE Diabetes and higher rates of gallbladder disorders in SCALE Obesity and Prediabetes. No new safety signals arose among early responders or early nonresponders.

In pooled analyses of the SCALE trials, women had slightly greater weight loss than men with liraglutide 3.0 mg [29](#oby21629-bib-0029){ref-type="ref"}; however, both men and women experienced a clinically meaningful weight loss. Consistent with this, there appeared to be more women than men among early responders to liraglutide 3.0 mg in both trials. Greater weight loss in women may in part be explained by higher plasma liraglutide exposure in women versus men [30](#oby21629-bib-0030){ref-type="ref"}.

The comparisons between early responders and early nonresponders must be interpreted with caution as they are not comparisons between randomized groups and were therefore not subjected to significance testing. In the case of the diabetes trial, conclusions are further limited by the low number of individuals in the liraglutide early nonresponder and placebo early responder groups. An additional limitation is the use of a forced dose escalation of liraglutide from 0.6 mg daily to 3.0 mg daily in 0.6 mg increments over 4 weeks (with 1 additional week at investigator\'s discretion) in the original trials. Also, early nonresponders in these trials were continued on treatment for 56 weeks; in clinical practice their treatment would be discontinued after 16 weeks, and improvements in end points might therefore be smaller than those reported here.

From a clinical perspective, use of the stopping rules should help optimize the use of liraglutide 3.0 mg for weight management. Patients can be informed that, if they respond well during the first 16 weeks, it is likely they will continue to do so. It is reassuring that most AEs were no more frequent in early responders compared with early nonresponders, even with greater weight loss, with the exception of gallbladder disorders, perhaps reinforcing the suggestion that at least part of the increased risk of gallbladder disorders seen in SCALE Obesity and Prediabetes was related to weight loss [14](#oby21629-bib-0014){ref-type="ref"}.

Conclusion {#oby21629-sec-0018}
==========

Weight loss of ≥4% after 16 weeks of treatment is a strong predictor of a clinically meaningful weight loss at 56 weeks. More individuals without or with T2D were early responders to liraglutide 3.0 mg in combination with lifestyle intervention compared with lifestyle intervention alone.

Among early responders to liraglutide 3.0 mg, greater mean weight loss, greater proportions achieving weight loss thresholds, and generally greater improvements in cardiometabolic risk factors and HRQoL scores were observed compared with early nonresponders.
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======================
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###### 

Click here for additional data file.
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